Combination of Near-Infrared Photoimmunotherapy Using Trastuzumab and Small Protein Mimetic for HER2-Positive Breast Cancer

Yamaguchi, Haruka; On, Jotaro; Mitsui, Takao; Suzuki, Takamasa; Okada, Yasuo; Ono, Junya; Evdokiou, Andreas

doi:10.3390/ijms222212213

Cited by 12 publications

(12 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Xia et al designed Z-M ADCN, a conjugate nanoagent self-assembled into nanomicelles, resulting in improved pharmacokinetics and in vivo targeting performance due to longer retention time in blood and higher drug accumulation in the tumor [ 303 ]. In addition, Yamaguchi et al evaluated the combination of Near-infrared photoimmunotherapy (NIR-PIT) with a HER2 Affibody-IR700Dye and a trastuzumab-IR700Dye conjugate in BC [ 304 ]. IR700Dye is a photosensitizer that, when irradiated with near-infrared light (690 nm), causes damage to the cell membrane and cell death without an effect on normal cells [ 305 ].…”

Section: Future Perspectives and Novel Strategies For Breast Cancermentioning

confidence: 99%

“…IR700Dye is a photosensitizer that, when irradiated with near-infrared light (690 nm), causes damage to the cell membrane and cell death without an effect on normal cells [ 305 ]. Both conjugates, which target different epitopes on HER2 protein, enhanced the effect of NIR-PIT against HER2-positive BC cells, including those with low HER2 expression, thus proposing a new therapeutic strategy for HER2 + -patients resistant to trastuzumab [ 304 ].…”

Section: Future Perspectives and Novel Strategies For Breast Cancermentioning

confidence: 99%

See 1 more Smart Citation

Advances of Epigenetic Biomarkers and Epigenome Editing for Early Diagnosis in Breast Cancer

Sarvari

Ramírez-Díaz

et al. 2022

IJMS

View full text Add to dashboard Cite

Epigenetic modifications are known to regulate cell phenotype during cancer progression, including breast cancer. Unlike genetic alterations, changes in the epigenome are reversible, thus potentially reversed by epi-drugs. Breast cancer, the most common cause of cancer death worldwide in women, encompasses multiple histopathological and molecular subtypes. Several lines of evidence demonstrated distortion of the epigenetic landscape in breast cancer. Interestingly, mammary cells isolated from breast cancer patients and cultured ex vivo maintained the tumorigenic phenotype and exhibited aberrant epigenetic modifications. Recent studies indicated that the therapeutic efficiency for breast cancer regimens has increased over time, resulting in reduced mortality. Future medical treatment for breast cancer patients, however, will likely depend upon a better understanding of epigenetic modifications. The present review aims to outline different epigenetic mechanisms including DNA methylation, histone modifications, and ncRNAs with their impact on breast cancer, as well as to discuss studies highlighting the central role of epigenetic mechanisms in breast cancer pathogenesis. We propose new research areas that may facilitate locus-specific epigenome editing as breast cancer therapeutics.

show abstract

Section: Future Perspectives and Novel Strategies For Breast Cancermentioning

confidence: 99%

Section: Future Perspectives and Novel Strategies For Breast Cancermentioning

confidence: 99%

Advances of Epigenetic Biomarkers and Epigenome Editing for Early Diagnosis in Breast Cancer

Sarvari

Ramírez-Díaz

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Meanwhile, the HER2 affibody-IR700 conjugate leads to necrotic cell death only in HER2-overexpression cancer cells following NIR light irradiation, without causing collateral damage to HER2 low-expressing cancer cells 93 , 124 . In addition, combination of the HER2 affibody-based conjugate and the trastuzumab-IR700 conjugate induces a strong therapeutic effect against HER2-positive cancer cells, including HER2 low-expressing cells, trastuzumab-resistant cells, and brain metastatic breast cancer cells 125 .…”

Section: Potential Application Of Nir-pit For Cancer Treatmentmentioning

confidence: 99%

Near-infrared photoimmunotherapy: design and potential applications for cancer treatment and beyond

Wei¹,

Qi²,

Hamblin³

et al. 2022

Theranostics

View full text Add to dashboard Cite

Near-infrared photoimmunotherapy (NIR-PIT) is a newly developed cancer treatment modality based on a target-specific photosensitizer conjugate (TSPC) composed of an NIR phthalocyanine photosensitizer and an antigen-specific recognition system. NIR-PIT has predominantly been used for targeted therapy of tumors via local irradiation with NIR light, following binding of TSPC to antigen-expressing cells. Physical stress-induced membrane damage is thought to be a major mechanism underlying NIR-PIT-triggered photokilling. Notably, NIR-PIT can rapidly induce immunogenic cell death and activate the adaptive immune response, thereby enabling its combination with immune checkpoint inhibitors. Furthermore, NIR-PIT-triggered “super-enhanced permeability and retention” effects can enhance drug delivery into tumors. Supported by its potential efficacy and safety, NIR-PIT is a rapidly developing therapeutic option for various cancers. Hence, this review seeks to provide an update on the (i) broad range of target molecules suitable for NIR-PIT, (ii) various types of receptor-selective ligands for designing the TSPC “magic bullet,” (iii) NIR light parameters, and (iv) strategies for enhancing the efficacy of NIR-PIT. Moreover, we review the potential application of NIR-PIT, including the specific design and efficacy in 19 different cancer types, and its clinical studies. Finally, we summarize possible NIR-PIT applications in noncancerous conditions, including infection, pain, itching, metabolic disease, autoimmune disease, and tissue engineering.

show abstract

“…Approximately one day after intravenous infusion of an IR700-based APC, NIR light is delivered to the cancer, activating a photochemical reaction that results in highly selective cancer cell killing while leaving normal tissues unaffected [ 4 , 5 , 6 , 7 ]. NIR-PIT has been used to target various cancer-specific proteins, such as epidermal growth factor receptor (EGFR) [ 8 , 9 , 10 , 11 , 12 , 13 ] and human epidermal growth factor receptor-2 (HER2) [ 14 , 15 , 16 , 17 , 18 , 19 ], and both have shown excellent anti-cancer effects. Furthermore, the clinical use of EGFR-targeted NIR-PIT progressed into clinical trials of patients with head and neck squamous cell carcinoma (HNSCC).…”

Section: Introductionmentioning

confidence: 99%

Near-Infrared Photoimmunotherapy (NIR-PIT) in Urologic Cancers

Fukushima

Türkbey

Pinto

et al. 2022

Cancers

View full text Add to dashboard Cite

Near-infrared photoimmunotherapy (NIR-PIT) is a novel molecularly-targeted therapy that selectively kills cancer cells by systemically injecting an antibody-photoabsorber conjugate (APC) that binds to cancer cells, followed by the application of NIR light that drives photochemical transformations of the APC. APCs are synthesized by selecting a monoclonal antibody that binds to a receptor on a cancer cell and conjugating it to IRDye700DX silica-phthalocyanine dye. Approximately 24 h after APC administration, NIR light is delivered to the tumor, resulting in nearly-immediate necrotic cell death of cancer cells while causing no harm to normal tissues. In addition, NIR-PIT induces a strong immunologic effect, activating anti-cancer immunity that can be further boosted when combined with either immune checkpoint inhibitors or immune suppressive cell-targeted (e.g., regulatory T cells) NIR-PIT. Currently, a global phase III study of NIR-PIT in recurrent head and neck squamous cell carcinoma is ongoing. The first APC and NIR laser systems were approved for clinical use in September 2020 in Japan. In the near future, the clinical applications of NIR-PIT will expand to other cancers, including urologic cancers. In this review, we provide an overview of NIR-PIT and its possible applications in urologic cancers.

show abstract

Combination of Near-Infrared Photoimmunotherapy Using Trastuzumab and Small Protein Mimetic for HER2-Positive Breast Cancer

Cited by 12 publications

References 37 publications

Advances of Epigenetic Biomarkers and Epigenome Editing for Early Diagnosis in Breast Cancer

Advances of Epigenetic Biomarkers and Epigenome Editing for Early Diagnosis in Breast Cancer

Near-infrared photoimmunotherapy: design and potential applications for cancer treatment and beyond

Near-Infrared Photoimmunotherapy (NIR-PIT) in Urologic Cancers

Contact Info

Product

Resources

About